Bad medicine? An effects-based approach to ‘pay-for-delay’ agreements

In July 2013, the European Commission, for the first time, fined pharmaceutical companies for settling a patent dispute via what it terms as ‘pay-for-delay’ agreements. Under these deals, generics producers agree to delay launching their (less-expensive) drug in exchange for a payment from the branded company. The Commission has treated the agreements as illegal per se—but do deals of this type necessarily harm consumers?

Read More

The economist as outsider

Can economists look at the world from the perspective of an outsider: detached, disengaged, objective? Diane Coyle, Enlightenment Economics, discusses why the answer is ‘no’. Unlike Camus’  Outsider , economists are right at the heart of the societies they study. Change is needed, in terms of economists’ methodologies and approaches to policy applications

Read More

What are the merits of appeals on the merits?

Consulting on the future of regulatory and competition appeals, the UK government is proposing substantial reforms, including a move away from appeals on the merits towards a judicial review standard. Oxera’s response to the consultation, summarised here, sets out why such a move may be unappealing

Read More

Open menu Close Search Play video RSS Feed Share on Facebook Share on Twitter Follow us on Instagram Follow us on Youtube Connect with us on Linkedin Email us Copy link